Survodutide vs Retatrutide

GLP-1 / glucagon dual agonist vs GLP-1 / GIP / glucagon triple agonist · Head-to-head comparison

Both add glucagon receptor activity to GLP-1. Retatrutide also keeps GIP; survodutide does not. Both are investigational, so this is a comparison of two unfinished programs.

Side by side

 SurvodutideRetatrutide
ClassGLP-1 / glucagon dual agonistGLP-1 / GIP / glucagon triple agonist
StatusPhase 3 investigationalPhase 3 investigational
RouteSubcutaneous injectionSubcutaneous injection
Typical vials5 mg, 10 mg, 15 mg5 mg, 10 mg, 15 mg, 30 mg
Dose range0.6 mg to 4.8 mg2 mg to 12 mg
FrequencyOnce weeklyOnce weekly
Half-life~7 days~6 days
Dosing unitmilligramsmilligrams

Pharmacokinetics

Survodutide and Retatrutide concentration curves comparedPHARMACOKINETICSShape and timing, side by sideEach curve is normalized to its own peak, so this compares timing, not potency.05101520dayspeak0Survodutide (t1/2 ~7 days)Retatrutide (t1/2 ~6 days)peprecon.com

What the evidence supports

These grade how well each outcome has been studied in humans, never how well either compound works. A strong grade can sit on a negative result.

Both top out at the same tier of evidence: Human RCT. Where they differ is in which outcomes have been asked about, not in how well either has been studied overall.

Survodutide

OutcomeEvidence
MASH / liver fibrosisHuman RCT
Weight lossHuman RCT
Long-term safetyNo data

Retatrutide

OutcomeEvidence
Glycemic controlHuman RCT
Hepatic steatosis / MASLDHuman RCT
Weight lossHuman RCT
Long-term safetyNo data
Human RCTAt least one randomized controlled trial in people reports this outcome. The result may still have been negative.
No dataNo published evidence at any level that we could find.

How to choose

Retatrutide has the larger reported weight loss

From Phase 2. Survodutide's Phase 2 results are also substantial but smaller.

Survodutide has the more specific liver evidence

Its Phase 2 program included a dedicated MASH trial with biopsy endpoints, which is a harder endpoint than liver fat imaging.

Neither is approved

Both are Phase 3 programs in progress. Any material available now is research-grade.

At the syringe

At the default setup on each compound's own page, a 10 mg vial in 2 mL puts 50 mcg on every insulin unit, while a 10 mg vial in 2 mL puts 50 mcg on every unit. That is the number that decides whether a dose lands on a readable mark, and it is set by how much water goes in, not by the compound.

Full references

Survodutidefull reference pageRetatrutidefull reference pageChartreconstitution matrixPlannermodel a schedule